Panel Improves Diagnosis of Candida in Pediatric Patients
By LabMedica International staff writers Posted on 15 Jul 2015 |
In an investigational study of pediatric patients, a Candida test panel provided accurate, fast diagnosis with only 2 mL of blood.
Rapid detection of Candida enables faster initiation of targeted treatment and can reduce a patient's length of hospitalization by almost 9 days. A rapid negative result can prevent unnecessary administration of antimicrobials as well as prevent or reduce antimicrobial resistance.
T2 Biosystems, Inc. (Lexington, MA, USA) presented results from an investigational study evaluating its T2Candida Panel in pediatric patients at the 2015 American Society for Microbiology (ASM) general meeting in New Orleans (LA, USA). The study included 15 confirmed candidemia patients 5–12 years of age. The data presented showed that in each of the 15 patient samples, T2Candida was able to accurately identify the species in 3–5 hours, compared to 2–6 days for blood culture. For this study a manual pipetting protocol was adapted to enable detection from just 2 mL of blood compared to the 3 mL currently required for the standard loading procedure.
"Fast and accurate results have been a challenge to obtain in pediatric patients suspected of sepsis due to the volume of blood required by current diagnostic procedures," said Prof. Camille Hamula, Icahn School of Medicine, Mount Sinai Hospital, "This new loading procedure maintains the high accuracy and fast results of the T2Candida Panel but with lower sample volume, which could have an important impact on the lives of young patients at risk of sepsis." "We are encouraged by these findings demonstrating that our T2Candida Panel was able to provide accurate results from lower blood volumes, which is critical in the pediatric patient population," said John McDonough, T2 Biosystems president and CEO.
T2Candida Panel, the first sepsis pathogen diagnostic that provides species-specific results in 3–5 hours without need for blood culture, was cleared for marketing by the US Food and Drug Administration (FDA) in September 2014. T2Candida Panel performance was established in adult subjects; performance in neonates, infants, and pediatric patients has not been established.
Related Links:
T2 Biosystems
ASM 2015 presentation of study results
Rapid detection of Candida enables faster initiation of targeted treatment and can reduce a patient's length of hospitalization by almost 9 days. A rapid negative result can prevent unnecessary administration of antimicrobials as well as prevent or reduce antimicrobial resistance.
T2 Biosystems, Inc. (Lexington, MA, USA) presented results from an investigational study evaluating its T2Candida Panel in pediatric patients at the 2015 American Society for Microbiology (ASM) general meeting in New Orleans (LA, USA). The study included 15 confirmed candidemia patients 5–12 years of age. The data presented showed that in each of the 15 patient samples, T2Candida was able to accurately identify the species in 3–5 hours, compared to 2–6 days for blood culture. For this study a manual pipetting protocol was adapted to enable detection from just 2 mL of blood compared to the 3 mL currently required for the standard loading procedure.
"Fast and accurate results have been a challenge to obtain in pediatric patients suspected of sepsis due to the volume of blood required by current diagnostic procedures," said Prof. Camille Hamula, Icahn School of Medicine, Mount Sinai Hospital, "This new loading procedure maintains the high accuracy and fast results of the T2Candida Panel but with lower sample volume, which could have an important impact on the lives of young patients at risk of sepsis." "We are encouraged by these findings demonstrating that our T2Candida Panel was able to provide accurate results from lower blood volumes, which is critical in the pediatric patient population," said John McDonough, T2 Biosystems president and CEO.
T2Candida Panel, the first sepsis pathogen diagnostic that provides species-specific results in 3–5 hours without need for blood culture, was cleared for marketing by the US Food and Drug Administration (FDA) in September 2014. T2Candida Panel performance was established in adult subjects; performance in neonates, infants, and pediatric patients has not been established.
Related Links:
T2 Biosystems
ASM 2015 presentation of study results
Latest Microbiology News
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care